Sinha, R., Sinha, I., Calcagnotto, A., Trushin, N., Haley, J.S., Schell, T.D
U.YanJ.LuJ.YangC.TongQ
Recent reviews on chitosan nanoparticle-based drug delivery systems highlight this dual advantage of biomedical performance and economic feasibility, but also stress that regulatory standardization of chitosan quality (degree of deacetylation, molecular weight, impurity profile) is essential before these materials can be reliably integrated into oncology practice [222, 223]
These clear effects (observed through comparison with various comparators, including current weekly GLP1-RAs on the market) are complemented by interesting data on cardiovascular safety and efficacy (from post-hoc studies) regarding the incidence and progression of nephropathy and hepatic steatosis